[3]. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. 2024 ASCO. 1025. [4]. Modi, S., Jac...
[5]Hamilton E, Hurvitz S, Im S, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. 2024 ASCO. 1025. [6]Cortés J, Hurvitz SA, Im SA, et al. Trastuzumab...
[5] PS2-01: Dalpiciclib versus placebo in combination with letrozole or anastrozole as first-line treatment for women with HR+/HER2- advanced breast cancer: prespecified final analysis of progression-free survival of the phase 3 DAWNA-2 trial. SABCS 2024. [6] Lu YS, Mahidin EIBM, Azim ...
BRCA1/2 mutations occurred in 6.6% of patients with human epidermal growth factor receptor 2 (HER2/neu)‐positive breast cancer. However, BRCA mutation status did not affect survival outcomes in patients who had HER2/neu‐positive breast cancer....
1. WHO. International Agency of Cancer Research. Cancer Today. 2020. Available at: . Accessed September 2023 . 2. American Cancer Society. Lung Cancer Survival Rates. Available at: . Accessed September 2023 . 3. Liu S, et al. Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with ...
9. Wolpoe ME, Lutz ER, Ercolini AM, et al. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function a...
In this population-based study, which takes into account all of the women living in Cote d’Or (Côte d’Or Breast and Gynaecological Cancer Registry), we investigated the effect of the first-line treatment (ET or CT) on PFS and overall survival (OS) in luminal MBC patients. ...
Human epidermal growth factor receptor 2 status and survival Sixty-one percent of cases were HER2 positive. In univariate log-rank testing, HER2-positive patients were significantly more likely to relapse on tamoxifen, giving 5-year breast cancer-specific survival rates of 68% compared with 96% fo...
58, 59, 60, 61, 62, 63 The wide range of reported concordance rates between IHC and FISH assessment of HER2 status in breast cancer reflects, at least in part, the wide variation in methodology, instrumentation, and experience of the laboratories performing the testing. The sensitivity and ...
[2]Hamilton EP, Hurvitz SA, Im SA, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. 2024 ASCO. 1025. ...